Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Accumulated Depreciation for 4 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Depreciation rose 39.36% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (up 39.36% YoY), while the FY2025 annual figure was $8.5 million, up 42.78% from the prior year.
• Accumulated Depreciation improved to $9.1 million in Q1 2026 per ARTV's latest filing, from $8.5 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $9.1 million in Q1 2026 and bottomed at $3.5 million in Q4 2023.
• Historically, Accumulated Depreciation has averaged $6.7 million across 4 years, with a median of $6.8 million in 2025.
• Annual changes were most pronounced in 2024 — Accumulated Depreciation soared 67.7% — and 2026, when it jumped 39.36%.
• Artiva Biotherapeutics' Accumulated Depreciation stood at $3.5 million in 2023, then jumped by 67.7% to $5.9 million in 2024, then soared by 42.78% to $8.5 million in 2025, then advanced by 7.67% to $9.1 million in 2026.
• Business Quant data shows ARTV's Accumulated Depreciation at $9.1 million in Q1 2026, $8.5 million in Q4 2025, and $7.8 million in Q3 2025.